### GDPD3 Gene Overview

**Gene Symbol:** GDPD3

**Function:** The GDPD3 gene encodes an enzyme that exhibits phosphoric diester hydrolase activity, which is crucial for hydrolyzing lysoglycerophospholipids, leading to the production of lysophosphatidic acid (LPA) and corresponding amines. This gene plays a significant role in the metabolism of N-acylethanolamines, exhibiting preference for specific substrates such as lysophosphatidylcholine (lyso-PC), 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF), and N-acylethanolamine lysophospholipids. Importantly, it does not hydrolyze glycerophosphoinositol or glycerophosphocholine, indicating a specific enzymatic role.

### 1. Associated Genes
While the summaries did not specify other directly associated genes, GDPD3 is known to interact with metabolic pathways concerning lysophosphatidic acid and N-acylethanolamines. Some genes related to lipid metabolism and signaling pathways may be indirectly associated, but specific genes may vary based on study focus. Examples may include:

- **PLA2G4A (Phospholipase A2 group IVA)** - involved in the release of arachidonic acid which can intersect with the signaling pathways influenced by LPA.
- **NAPEPLD (N-acyl-phosphatidylethanolamine phospholipase D)** - involved in the metabolism of N-acylethanolamines.

### 2. Aging and Age-Related Diseases
While specific studies linking GDPD3 to aging or age-related diseases are limited, fatty acid metabolism and lysophosphatidic acid signaling have been suggested to play roles in:

- **Aging-related neurodegeneration:** LPA is known for its influence on various signaling pathways in the brain, and deregulation of LPA metabolism can impact neuroinflammatory processes or neurodegenerative diseases.
- **Cardiovascular diseases:** Dysregulation of lysophospholipid metabolism may be associated with conditions such as atherosclerosis, particularly relevant in aging populations.

### 3. Drug Interactions
As of the latest consensus, there are no specific drugs or drug classes widely acknowledged to directly target or influence GDPD3. However, potential interactions may arise with:

- **Lysophosphatidic acid receptor antagonists** - drugs developed to modulate LPA signaling pathways could have indirect effects on GDPD3 activity or expression.
- **Anti-inflammatory agents** - due to the gene's role in metabolic pathways affecting lipid signaling, drugs targeting inflammation might also influence its activity.

### 4. Pathways and Biological Processes
GDPD3 is involved in:

- **N-acylethanolamine metabolic process** - critical for the regulation of various physiological functions including pain modulation and neuroinflammatory responses.
- **Lysophosphatidic acid signaling pathway** - plays a pivotal role in cell proliferation, survival, migration, and potentially in cancer biology.
- **Endoplasmic reticulum-localized metabolic pathways** - highlighting its integral presence and role within cellular lipid metabolism projections.

Overall, GDPD3 is implicated in vital metabolic processes and potentially influences aging-related pathways, although further research is necessary to elucidate its full scope of biological impact and pharmacological relevance.